CN101143168A - Technology for preparing haw total phenolic acid part - Google Patents
Technology for preparing haw total phenolic acid part Download PDFInfo
- Publication number
- CN101143168A CN101143168A CNA2006101490499A CN200610149049A CN101143168A CN 101143168 A CN101143168 A CN 101143168A CN A2006101490499 A CNA2006101490499 A CN A2006101490499A CN 200610149049 A CN200610149049 A CN 200610149049A CN 101143168 A CN101143168 A CN 101143168A
- Authority
- CN
- China
- Prior art keywords
- total phenolic
- fructus crataegi
- effective site
- preparation
- phenolic acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007965 phenolic acids Chemical group 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 235000009048 phenolic acids Nutrition 0.000 claims description 13
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- -1 aliphatic alcohols Chemical class 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 4
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 2
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 claims description 2
- 235000004883 caffeic acid Nutrition 0.000 claims description 2
- 229940074360 caffeic acid Drugs 0.000 claims description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 2
- 241001055174 Asterinides folium Species 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 9
- 239000007924 injection Substances 0.000 abstract description 9
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 8
- 241001092040 Crataegus Species 0.000 abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 2
- 206010039966 Senile dementia Diseases 0.000 abstract description 2
- 230000000302 ischemic effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 3
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 3
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 3
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 3
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 3
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 3
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 3
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 3
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 3
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 3
- 230000000295 complement effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 16
- 239000003814 drug Substances 0.000 description 12
- 235000011949 flavones Nutrition 0.000 description 11
- 229930003944 flavone Natural products 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000002526 effect on cardiovascular system Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 150000002213 flavones Chemical class 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000001168 carotid artery common Anatomy 0.000 description 6
- 210000000269 carotid artery external Anatomy 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N nimodipine Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229940043316 hawthorn preparation Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000103 occipital bone Anatomy 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 210000003977 optic chiasm Anatomy 0.000 description 1
- 230000004413 optic chiasma Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a technology of extracting the total phenolic acid part of hawthorn from the hawthorn leaf or the hawthorn fruit. The part can be used separately or matched with other medically permissive complementary material to be made into an oral preparation and an injection preparation. The part is fit for preventing and remedying various kinds of ischemic cardio-cerebrovascular diseases, senile dementia and hyperlipoidemia.
Description
The application is that the application number submitted on August 26th, 2003 is dividing an application of 03150544.9 application for a patent for invention " preparation technology of haw total phenolic acid part and application "!
Technical field:
The invention belongs to field of medicaments, is to separate preparation technology, preparation and the potential application on medicine and health food that obtains total phenolic acid part from Folium Crataegi or fruit specifically.
Background technology:
Cardiovascular and cerebrovascular disease is one of present countries in the world sickness rate disease with high.Along with The development in society and economy, the raising of living standards of the people, the prevalence of cardiovascular and cerebrovascular disease is also increasing year by year.According to interrelated data, calendar year 2001 the whole world 5,600 ten thousand people's death are arranged.Two kinds of main diseases of coronary heart disease and apoplexy are because of relevant with 7,000,000 and 5,500,000 people's death respectively.Just because of this, the research and the control of cardiovascular and cerebrovascular disease all paid much attention in countries in the world.But up to the present, although many cardiovascular and cerebrovascular vessel medicines are arranged in clinical practice, the treatment cardiovascular and cerebrovascular disease has been brought into play good effect, but and fail to control the impetus that the cardiovascular and cerebrovascular disease prevalence increases, this reflects from a side also needs to carry out continuous effort, develop more effective new drug, put into clinical practice.Owing to the economic development imbalance, the medical expense of cardiovascular and cerebrovascular vessel can not well be treated many patients at present simultaneously, also needs to develop and can satisfy the new drug extensive patients needs, that price is lower, for the control cardiovascular and cerebrovascular disease is contributed.
Fructus Crataegi is the Rosaceae Crataegus plant, and there is kind surplus this platymiscium 280 in the whole world, in state-owned 19 kinds.Its fruit is a conventional Chinese medicine, also is China's pharmacopeia kind.Put down in writing according to Compendium of Material Medica: these product " sour sugariness temperature, it is long-pending to help digestion, spleen reinforcing ".Containing multiple physiologically active ingredient in its fruit, as flavones ingredient, ursolic acid, oleanolic acid, chlorogenic acid, organic acid, mineral and trace element etc., have multiple pharmacological effect, is the important living resources of China, is classified as the dietotherapeutic kind by country.After the fifties, research worker finds that Folium Crataegi also has multiple physiologically active.Studying more is the Folium Crataegi total flavones constituents, the extract and the Folium Crataegi total flavones preparation (as Yixintong sheet and capsule) of existing several Folium Crataegi total flavoness at present, the treatment that is mainly used in diseases such as coronary heart disease, hyperlipidemia.
What think performance pharmacological action in the Fructus Crataegi at present is wherein total flavonoid composition, also have some separation and Extraction patents about Fructus Crataegi total flavones (as application number be: 01103986.8 and application number be: 01118628.3), but we are through discovering, after the flavones content in the Fructus Crataegi total flavones extract was further improved, activity descended on the contrary.What this pointed out in our Fructus Crataegi performance pharmacological action may be the non-flavones ingredient in the Fructus Crataegi.
Summary of the invention:
The invention provides a kind of preparation method that obtains haw total phenolic acid part of from Folium Crataegi or fruit, separating, reach the potential using value of this position in medicine and health food.
In accordance with the following methods, we have obtained haw total phenolic acid part.That is: with Folium Crataegi or fruit through hydrous alcohol extraction, the extracting solution concentrating under reduced pressure is placed precipitation, supernatant is through macroporous adsorption resin chromatography, and water elution is used ethyl acetate extraction after partly regulating pH value to 1～2, behind the extract concentrating under reduced pressure with water dissolution, through macroporous adsorption resin chromatography, behind the water elution, continuous again with aqueous alcohol or aqueous acetone eluting, the eluent concentrating under reduced pressure, spray drying obtains yellow powder, is haw total phenolic acid part.
Medical material used in the present invention can be Folium Crataegi or Fructus Crataegi, but the total phenolic content in the Folium Crataegi will be higher than Fructus Crataegi, and because of sugar and content of starch height in the Fructus Crataegi, and the price of Folium Crataegi is more cheap than Fructus Crataegi, therefore, the actual Folium Crataegi that uses is better than Fructus Crataegi.
The employed aqueous alcohol of this technology can be the lower aliphatic alcohols of methanol, ethanol and other C1～C5.The concentration of extracting used aqueous alcohol is 50%～90%, and the eluting macroporous adsorbent resin adopts 20%～60% aqueous alcohol or aqueous acetone.
The macroporous adsorbent resin that this technology adopted comprises various nonpolar, low poles, Semi-polarity, polar homemade or import macroporous adsorbent resin.
Above-mentioned effective site contains phenolic acid compositions such as caffeic acid, caffeoyl guinic acid compounds, caffeoyl threose acid compounds.The content of using the chemical constituent that HPLC was familiar with occupies imitates more than 50% of position.
Utilize this effective site to can be made into various clinically preparations: injection, powder ampoule agent for injection, oral tablet, electuary, capsule, drop pill, oral liquid etc.
Above-mentioned preparation can be used for preventing and treating the application of various ischemic cardio cerebrovascular diseases, senile dementia, hyperlipidemia aspect.
Following animal experiment study further illustrates haw total phenolic acid part useful effect of the present invention:
1. acute toxicity test
40 of healthy Kunming mouses, male and female half and half, body weight 18～22g; 40 of healthy SD rats, male and female half and half are about body weight 150g.
The orally give haw total phenolic acid part can not surveyed LD
50Value is so its maximum tolerated dose to mice and rat (MTD) is measured in this experiment respectively.Big mice all gavages administration by maximum administration volume, and morning and afternoon respectively once.The mice fasting be can't help water 5 hours before the administration, and the rat fasting be can't help water 12 hours.
Experimental result shows: mice oral haw total phenolic acid part 2.2g/kg (gavaging at twice) on the one, can cause reactions such as independent activity of animals reduces, appetite descends, body weight gain is slow, and above-mentioned being reflected at recovered in two weeks, do not cause animal dead.The maximum tolerated dose that the oral haw total phenolic acid part of mice is described is greater than 2.2g/kg (be equivalent to clinical dosage 550 times).
Rat oral haw total phenolic acid part 2.8g/kg (gavaging at twice) on the one can cause degradation reaction under independent activity of animals minimizing, the appetite, and above-mentioned being reflected in two weeks recovered, and do not cause animal dead.The maximum tolerated dose that the oral haw total phenolic acid part of mice is described is greater than 2.8g/kg (be equivalent to clinical dosage 700 times).
2. to the influence of focal cerebral ischemia in rats
Get 70 of male SD rats, body weight 300～400g, be divided into 6 groups at random by body weight, be respectively Fructus Crataegi total phenolic acids high dose group (8mg/kg), middle dosage group (4mg/kg), low dose group (2mg/kg), positive control nimotop group (1.2mg/kg), sham operated rats and ischemia model matched group (all giving equivalent 0.5%CMC-Na).
7d before experiment, every day, ig was 1 time, 60min administration before ischemia for the last time in the 7th day.Adopt internal carotid artery line bolt legal system to be equipped with intraluminal middle cerebral artery occlusion in rats obturation (MCAO) model.Rat is anaesthetized with 10% chloral hydrate (300mg/kg) ip, the cervical region median incision on the constant temperature operating-table of lying on the back, expose right carotid, outwards draw digastric and sternocleidomastoid, free successively by common carotid artery crotch head-end, ligation and the branch of cutting off external carotid artery: tremulous pulse and superior thyroid artery under the occipital bone, in the ligation of external carotid artery far-end, cutting off external carotid artery makes its trunk free standby, separate internal carotid artery then, make a call to one with silk thread at the external carotid artery root and release, folder closes common carotid artery and internal carotid artery.Nylon wire through external carotid artery trunk otch, is slowly gone into the cranium direction to internal carotid artery and advanced, and is labelling with the common carotid artery crotch, feel resistance when advancing the 20mm left and right sides, promptly reached in the thinner anterior cerebral artery, all blood of having blocked MCA are tightened the external carotid artery root and are released for the source.Behind the 1h, extract nylon wire, tighten the tremulous pulse stump.Skin suture is finished MCAO and is caused focal cerebral ischemia-irritate again model.Behind the sham operated rats rat anesthesia, only expose the inside and outside aortic bifurcation of neck, not inaccessible middle cerebral artery.Postoperative 24h carries out rank scores by the method for Bederson to the behavioral deficiency of animal.Behind the MCAO24h, the sacrificed by decapitation rat is taken out full brain, and left and right sides brain cuts respectively, weighs.At right brain optic chiasma and each 2mm place, front and back thereof, do crown section, brain section lucifuge in 1%TTC solution is hatched 25min for 37 ℃, separates pale district (infarct) and non-pale district (normal district), calculates infraction percentage ratio.With the oven dry of the cerebral tissue after the dyeing, contrast brain weight in wet base is obtained brain water content.
Experimental result shows: the result shows, behind rat ig Fructus Crataegi total phenolic acids 2,4, the 8mg/kg, animal behavior variation and infarction size and normal saline matched group relatively have clear improvement, and behavior scoring has reduced by 43.25% (p＜0.01), 60.70 (p＜0.001), 63.88 (p＜0.001) respectively behind the 24h; Cerebral infarct size has on average dwindled 30.2% (p＜0.01), 47.3 (p＜0.01), 50.9 (p＜0.001).High dose group is suitable with nimotop group action intensity.2) to the influence of focal rats with cerebral ischemia biochemical indicator get 70 of male rats (300～400g), the grouping administration, operation method such as preceding.Behind the MCAO 24h, the rat sacrificed by decapitation is got brain, removes cerebellum.Brain is made 10% homogenate with normal saline, measure the superoxide dismutase (SOD) in the cerebral tissue, glutathion (GSH), the content of malonaldehyde (MDA) and lactic acid (LA) etc.Experimental result shows: Fructus Crataegi total phenolic acids can make the interior MDA of cerebral tissue of rat reperfusion injury, and the LA equal size reduces, and shows that tissue ischemia anoxia and peroxidating degree are subjected to obvious inhibition; SOD and GSH content increase simultaneously, have reflected that medicine has raising to antioxidant ability of organism and the ability of removing free radical.
3. to the therapeutical effect and the hemodynamic effects of dog myocardial ischemia
30 of dogs are divided into 6 groups.Left anterior descending coronary artery (LAD) sham-operation normal saline group, LAD blocking-up normal saline group, LAD blocking-up Propranolol group, 3 dosage groups of LAD blocking-up Fructus Crataegi total phenolic acids (2,4,8mg/kg).Iv pentobarbital sodium 30mg/kg anesthesia, tracheal intubation pedestrian worker breathes, and the 4th intercostal is opened breast in a left side, separates the LCA root, places the electromagnetic flowmeter probe, the record blood flow.Common carotid artery intubate record common carotid artery blood pressure.Measure left constant pressure from apex of the heart intubate to left chamber, and measure left chamber diastasis and left ventricular pressure rate of change maximum.With heart rate instrumentation centering rate, observe the II lead electrocardiogram simultaneously.After postoperative is stablized 10min,, be data before the administration in the above-mentioned all indexs of RM-6000 type physiograph.The vena femoralis injection administration, ligation LAD behind the 5min, record LAD blocking-up back 1,2,5,10,20,30,60,90,120,240, the above-mentioned all indexs during 360min (data behind the medicine).Before administration and after the administration 20,40,60,90,120min gets blood simultaneously from coronary sinus vein and common carotid artery, measures oxygen content with CORNING178 type blood gas analyzer.Calculating myocardium blood flow, coronary resistance, myocardial oxygen consumption, myocardial oxygen consumption index, myocardium coefficient of oxygen utilization.
Result of the test shows that infusion haw total phenolic acid part 2mg/kg does not have obvious influence to the every index of hemodynamics; 4,8mg/kg can obviously increase myocardial flow, reduces coronary resistance, significantly reduces myocardial oxygen consumption and myocardial oxygen consumption index, reduces myocardium coefficient of oxygen utilization.
4. to Carnis Coturnicis japonicae hyperlipemia and atherosclerotic effect
Get 60 of healthy male Carnis Coturnicis japonicaes, be divided into 6 groups at random, 10 every group.Normal feedstuff group; Hyperlipidemia model group: feed high lipid food (including 79% normal feedstuff, 1% cholesterol, 20% Adeps Sus domestica); Haw total phenolic acid part is little, in, heavy dose of group 40,80 and 160mg/kg.d; Lovastatin positive controls 4mg/kg.d.Give normal feedstuff and hyperlipidemia model group except that the normal control group and give the high lipid food, each group is given different medicines respectively when giving high lipid food.Each treated animal sub-cage rearing, quantitative feeding, administration every day 1 time, jugular vein is got blood behind the successive administration 60d, measure serum TC, TG and HDL-C respectively, LDLC-C by formula LDL-C=TC-(1/2.2TG+HDLC-C) calculates, and puts to death animal then, take out aorta and liver, observe sick damage situation of arterial wall and liver fat denaturation degrees.
Experimental result shows: 1) to after the influencing Carnis Coturnicis japonicae and gavage haw total phenolic acid part 60d of blood fat, middle dosage group (80mg/kg.d) can obviously reduce the content (p＜0.05) of serum TC, TG and LDL-C, reduces percentage rate and is respectively 36.21%, 29.18% and 35.27%.Heavy dose of group (160mg/kg.d) can significantly reduce the content (p＜0.01) of serum TC, TG and LDL-C, reduce percentage rate and be respectively 47.29%, 43.38% and 45.87%, simultaneously can make TC/HDL-C ratio obviously reduce (p＜0.05), reducing percentage rate is 36.92%.2) to atherosclerotic plaque form influence Carnis Coturnicis japonicae and gavage haw total phenolic acid part after, plaque area percentage rate and average gray can descend 7.3%～29.8% and 8.4%～21.9% respectively 3 kinds of various dose groups, and heavy dose of group reduces the effect highly significant (p＜0.01) of plaque area percentage rate and average gray.The microscopically observation also higher fat model group of aortic tunica intima thickness of visible haw total phenolic acid part group is thin, and the foam cell number of appearance is also less.3) to after the influencing Carnis Coturnicis japonicae and gavage haw total phenolic acid part 80mg/kg and 160mg/kg 60d of liver, the liver weight coefficient has obvious reduction (p＜0.01).The hepatic tissue section microscopy also higher fat model group of fatty degeneration of liver degree of visible medication group obviously alleviates.Above-mentioned experimental result shows that haw total phenolic acid part has tangible blood fat reducing and the atherosis effect of prevention of arterial.
The present invention has the following advantages or good effect compared with the prior art:
1. with respect to other some cardiovascular medicaments, Folium Crataegi or fruit have sufficient raw, low price, and cost is low.
2. prior art it is generally acknowledged that the active site of Fructus Crataegi is a total flavonoid composition wherein.Our result of study shows that the activity of haw total phenolic acid part is better than the Fructus Crataegi total flavones position.
3. existing all is Fructus Crataegi total flavones constituents at wherein about Fructus Crataegi extract and preparation.The invention provides the preparation technology, quality standard of haw total phenolic acid part and in pharmaceutically application.
4. the quality standard of extract of existing Fructus Crataegi and preparation is to measure content of total flavone to formulate, and assay method is also many to be measured with ultraviolet method, and because of ultraviolet method disturbs greatly, assay method is inaccurate.And the present invention uses HPLC method mensuration, and wherein recognizable content of effective reaches more than 50%.
5. because the difference of composition is existing about the hawthorn preparation poorly water-soluble, generally can only make oral formulations, as tablet, capsule, drop pill.And the haw total phenolic acid part that we obtain can be made the several formulations that comprises injection type.
Description of drawings:
Fig. 1 is the extraction process flow chart of haw total phenolic acid part of the present invention.
The specific embodiment:
Embodiment one: the preparation of effective site
Get exsiccant Folium Crataegi 100kg, be ground into coarse powder, divide reflux, extract, three times with 10 times of amount 60% ethanol, merge extractive liquid, is evaporated to 50L, places precipitation, centrifugal, supernatant is through the AB-8 macroporous adsorption resin chromatography, and water elution is used ethyl acetate extraction after partly regulating pH value to 1, behind the extract concentrating under reduced pressure with water dissolution, through the AB-8 macroporous adsorption resin chromatography, be 3～5 again, continue rare acetone eluting with 60% with water elution to pH value, the eluent concentrating under reduced pressure, spray drying obtains buff powder 0.52kg, is haw total phenolic acid part (is 0.52% by crude drug amount yield).Through assay, purity is 84.79%.
Embodiment two: the preparation of effective site
Get exsiccant Fructus Crataegi 100kg, pulverize, divide percolation to extract with 20 times of amount 80% methanol, merge percolate, be evaporated to 50L, place precipitation, centrifugal, supernatant is through the D101 macroporous adsorption resin chromatography, and water elution is used ethyl acetate extraction after partly regulating pH value to 2, behind the extract concentrating under reduced pressure with water dissolution, through the AB-8 macroporous adsorption resin chromatography, be 3～5 again, continue Diluted Alcohol eluting with 20% with water elution to pH value, the eluent concentrating under reduced pressure, spray drying obtains buff powder 0.42kg, is haw total phenolic acid part (is 0.42% by crude drug amount yield).Through assay, purity is 67.25%.
Embodiment three: the preparation of tablet
Get position 100g of the present invention, starch 80g, dextrin 5g mix homogeneously, add 10% starch slurry system soft material, granulate with 14 order nylon screens, 60～70 ℃ of aeration-dryings, 16 mesh sieve granulate add magnesium stearate 1.5g, carboxymethyl starch and receive the 5g mixing, be pressed into 1000, coating promptly.Every contains position 100mg of the present invention.Adult every day 2～5 times, each 1～10.
Embodiment four: the preparation of oral liquid
Get position 20g of the present invention, mix with Mel 30g, sucrose 50g, sodium benzoate 2g and distilled water 300ml, be heated to 85～90 ℃, stir and make dissolving, insulation 30min filters, and the filtrate thin up stirs evenly to 1000ml, embedding (every 10ml), and sterilization is promptly.Adult every day 2～5 times, each 1～5.
Embodiment five: the preparation of injection
Get position 50g of the present invention, add the injection water and make dissolving in right amount, 0.02% active carbon that adds amount of preparation stirs 5～10min, filter, filtrate is diluted to about 10L, adds sodium chloride adjusting osmotic pressure and oozes to waiting, regulate pH5.5～7.5, ultrafiltration, embedding become 1000 (10ml/ props up), and 100 ℃ of 30min sterilizations promptly.Adult's vein or administered intramuscular, every day 1～2 time, each 1～5.
Embodiment six: the preparation of injectable powder
Get position 50g of the present invention, add the injection water and make dissolving in right amount, 0.02% active carbon that adds amount of preparation stirs 5～10min, filters, and filtrate is diluted to 1L, regulates pH5.5～7.5, ultrafiltration, and spray drying, dry powder is promptly aseptic subpackaged.Every 50mg faces with before adding the injection water and makes dissolving in right amount, with the slowly intravenous drip of sodium chloride transfusion 100～500ml dilution back.Adult every day 1～2 time, each 1～5.
Claims (6)
1. the preparation method of a Fructus Crataegi total phenolic acids effective site is characterized in that, this method comprises the following steps:
A. Folium Crataegi or fruit after crushed, with hydrous alcohol extraction, the extracting solution concentrating under reduced pressure is placed precipitation;
B. supernatant is through macroporous adsorption resin chromatography, and water elution is partly regulated pH value to 1-2;
C. ethyl acetate extraction, behind the extract concentrating under reduced pressure with water dissolution, again through macroporous adsorption resin chromatography, aqueous alcohol or aqueous acetone eluting;
D. eluent concentrating under reduced pressure, spray drying obtains buff powder, is Fructus Crataegi total phenolic acids effective site.
2. the preparation method of Fructus Crataegi total phenolic acids effective site according to claim 1 is characterized in that, described Fructus Crataegi total phenolic acids effective site is total phenolic acid effective site of extracting from Folium Crataegi or fruit, wherein content＞50% of total phenolic acid.
3. the preparation method of Fructus Crataegi total phenolic acids effective site according to claim 1 is characterized in that, described Fructus Crataegi total phenolic acids effective site contains caffeic acid, caffeoyl guinic acid compounds, caffeoyl threose acid compounds.
4. the preparation method of Fructus Crataegi total phenolic acids effective site according to claim 1 is characterized in that, the alcohol among described step a. and the c. is the lower aliphatic alcohols of methanol, ethanol and other C1-C5.
5. the preparation method of Fructus Crataegi total phenolic acids effective site according to claim 1 is characterized in that, the concentration of the aqueous alcohol among the described step a. is 50%-90%.
6. the preparation method of Fructus Crataegi total phenolic acids effective site according to claim 1 is characterized in that, the aqueous alcohol in the described step c or the concentration of aqueous acetone are 20%-60%.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031505449A CN100421689C (en) | 2003-08-26 | 2003-08-26 | Preparation technology of crataegus total phenolic acid portion and application |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031505449A Division CN100421689C (en) | 2003-08-26 | 2003-08-26 | Preparation technology of crataegus total phenolic acid portion and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101143168A true CN101143168A (en) | 2008-03-19 |
Family
ID=34597580
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101490499A Pending CN101143168A (en) | 2003-08-26 | 2003-08-26 | Technology for preparing haw total phenolic acid part |
| CNB031505449A Expired - Fee Related CN100421689C (en) | 2003-08-26 | 2003-08-26 | Preparation technology of crataegus total phenolic acid portion and application |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031505449A Expired - Fee Related CN100421689C (en) | 2003-08-26 | 2003-08-26 | Preparation technology of crataegus total phenolic acid portion and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN101143168A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20121749A1 (en) * | 2012-10-16 | 2014-04-17 | Indena Spa | HELIANTHUS ANNUUS EXTRACTS USEFUL IN THE TREATMENT OF THE METABOLIC SYNDROME AND IN THE DECREASE OF THE GLICEMIC FOOD INDEX AND PROCEDURE FOR THEIR PREPARATION AND THE COMPOSITIONS THAT CONTAIN THEM |
| CN106389568B (en) * | 2016-11-07 | 2019-06-11 | 中国农业科学院郑州果树研究所 | A kind of pear ripe fruit total phenol extraction method |
| CN112675228B (en) * | 2021-01-18 | 2021-12-28 | 南京邮电大学 | A kind of ointment for promoting wound healing and preparation method thereof |
| CN114031588B (en) * | 2021-11-02 | 2024-06-18 | 东营市人民医院 | Phenol derivative, preparation method thereof and application of phenol derivative in preparation of anti-inflammatory and/or antioxidant drugs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1027574C (en) * | 1991-05-08 | 1995-02-08 | 安阿玥 | Preparation method of injection for treating hemorrhoids |
-
2003
- 2003-08-26 CN CNA2006101490499A patent/CN101143168A/en active Pending
- 2003-08-26 CN CNB031505449A patent/CN100421689C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100421689C (en) | 2008-10-01 |
| CN1589845A (en) | 2005-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101182917B1 (en) | Medicinal composition containing ginseng secondary glycosides, its preparation method and application | |
| CN101033245B (en) | Preparation method and application of pedunculoside | |
| CN1931236B (en) | Medicine composition of red sage and rhodiola root | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN100421689C (en) | Preparation technology of crataegus total phenolic acid portion and application | |
| WO2013007092A1 (en) | Medicament for treatment of coronary heart diseases and angina pectoris and preparation method therefor | |
| US20070213280A1 (en) | Steroidal Saponins Compound, the Process for Producing the Same and the Use Thereof | |
| CN101099754A (en) | Preparation method and application for pedunculoside II | |
| CN101961340B (en) | Application of pedunculoside in preparing medicine for treating coronary heart disease | |
| CN101032534B (en) | Method of preparing Ilex rotunda Thunb total saponins and the application thereof | |
| CN101293009A (en) | Pharmaceutical composition | |
| CN101974011A (en) | New compound methyl brevicate with medical activity | |
| CN1239164C (en) | Haw effective part and its extracting method and uses | |
| CN101176751B (en) | Pharmaceutical composition of red sage root and cassia twig | |
| CN101696166B (en) | Preparation method of salvianolic acid A from salvia miltiorrhiza | |
| CN101982175B (en) | Application of pedunculoside in preparing medicine for treating cerebral ischemia | |
| CN112353837B (en) | Flos puerariae extract and its use | |
| CN102078344A (en) | Ilicis routundae cortex pharmaceutical composition and application thereof | |
| CN103505488A (en) | Traditional Chinese medicine composition of pseudo-ginseng and sea-buckthorn and preparation method of composition | |
| CN101190253B (en) | Medicinal composition containing mongolian snakegourd and notoginseng | |
| CN102070700A (en) | Marsdenia tenacissima saponins H and preparation method and application thereof | |
| CN101129430A (en) | Traditional Chinese medicine composition used for preventing and controlling cardiovascular disease, processes for producing same and application of the same | |
| CN100396297C (en) | Compsn. of Chinese traditional medicine in use for treating cardiovascular diseases | |
| CN101104029A (en) | Medicinal compositions | |
| CN101176769A (en) | Pharmaceutical composition of cattail pollen and red orpin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080319 |